PRKCA and Alzheimer disease: Conversely, treatment with CSF from non-AD subjects provided different expression profiles because of a general downregulation at 24 h and slight βcat, Prkca, and Gnao mRNA level increases at 48 h while the others were unaffected or remained downregulated.